Noninvasive fecal testing for colorectal cancer
2021
Abstract Introduction Colorectal cancer (CRC) is the third most common malignancy worldwide, with the second highest mortality rate among all malignancies. In this review, we describe the current utility of stool diagnostic biomarkers for CRC. Methods We reviewed stool-related tests and biomarker candidates for the diagnosis of CRC. The guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and multitarget stool DNA test (MT-sDNA) have been used as clinical CRC screening tools. Although microRNAs, protein biomarkers, and microbiota have not yet been used in clinical CRC screening, there is growing evidence that they have the potential to function as CRC screening tools. Results According to the literature, the sensitivity of MT-sDNA for detecting CRC was 87.0%-100%, 32.7%-82.0% for advanced adenomas, and the specificity was 86.1%-95.2%. The sensitivity of individual biomarkers of fecal microRNAs for detecting CRC was 34.2%-88.2%, 73.0% for advanced adenomas, and the specificity was 68%-100%. The sensitivity of fecal protein markers for detecting CRC was 63.6-93.0%, 47.7%-69.4% for advanced adenomas, and the specificity was 38.3%-97.5%. The sensitivity of fecal microbiota for detecting CRC was 54.0-100.0%, 32.0%-48.3% for advanced adenomas, and the specificity was 61.3%-90.0%. Conclusion MT-sDNA is the most sensitive CRC screening test, and its sensitivity is the highest for advanced adenomas; however, its detection cost is high. MT-sDNA was more sensitive to CRC and advanced precancerous lesions than FIT, but compared to three years of MT-sDNA, annual FIT as the first non-invasive screening test for CRC seemed to be more effective.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
90
References
0
Citations
NaN
KQI